

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Reporting Issuer**

Doseology Sciences Inc. (the “Company”)  
Suite 305, 9–3151 Lakeshore Rd.  
Kelowna, BC V1W 3S9

**Item 2: Date of Material Change**

May 8, 2024.

**Item 3: News Release**

A news release was issued and disseminated May 13, 2024 and filed on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

**Item 4: Summary of Material Changes**

The Company announced officer changes. See item 5 for further details.

**Item 5: Full Description of Material Change**

The Company announced the appointment of Christopher P. Cherry as CFO of the Company. Mr. Cherry joins the Company at a pivotal moment as Doseology accelerates its expansion in the Canadian retail market with new distribution partners. With a focus on innovation, Doseology is set to diversify its portfolio of brands within the supplement category, catering to the evolving needs of consumers.

Bringing over 15 years of corporate accounting and audit experience, Mr. Cherry's expertise will ensure the company's financial stability and growth. His previous roles include Director, CFO, and Secretary for several public companies across a broad range of sectors. Mr. Cherry, a Chartered Accountant since February 2009, has specialized in auditing junior public companies and IPOs during his tenure at KPMG and Davidson and Co. LLP in Vancouver.

To accommodate the appointment of Christopher P. Cherry as CFO, Shawn Balaghi has resigned as Interim CFO. However, Mr. Balaghi will continue to serve as a member of the board of directors and as the Interim CEO of the Company.

**Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

Not applicable.

**Item 8: Executive Officer**

For further information, please contact:

Daniel Vice, Co-Founder and Director  
Investor Relations: [investor@doseology.com](mailto:investor@doseology.com)  
General Inquiries: [hello@doseology.com](mailto:hello@doseology.com)  
Telephone: +1 825-800-0115

**Item 9: Date of Report**

May 13, 2024.